Global Pernicious Anemia Testing Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Pernicious Anemia Testing Market Size

• The global pernicious anemia testing market size was valued at USD 19.03 billion in 2024 and is expected to reach USD 28.33 billion by 2032, at a CAGR of 5.10% during the forecast period
• The market growth is largely fueled by the rising prevalence of vitamin B12 deficiency, advancements in diagnostic technologies, and increasing awareness about early detection and treatment of pernicious anemia across populations
• Furthermore, growing demand for accurate, non-invasive, and cost-effective diagnostic solutions in hospitals, clinics, and home care settings is establishing modern testing methods as the preferred choice for clinicians and patients. These converging factors are accelerating the adoption of pernicious anemia testing, thereby significantly boosting the industry's growth

Pernicious Anemia Testing Market Analysis

• Pernicious anemia testing, involving diagnostic evaluation for vitamin B12 deficiency and intrinsic factor antibodies, is increasingly vital in modern healthcare due to its ability to enable early detection, prevent complications, and guide effective treatment strategies across diverse patient populations
• The escalating demand for pernicious anemia testing is primarily fueled by the rising prevalence of vitamin B12 deficiency, growing awareness of anemia-related health risks, and the adoption of advanced, non-invasive diagnostic technologies
• North America dominated the pernicious anemia testing market with the largest revenue share of 38.2% in 2024, characterized by advanced healthcare infrastructure, high awareness levels, and a strong presence of key diagnostic companies, with the U.S. experiencing substantial growth in testing rates, particularly in aging populations and patients with chronic conditions, driven by innovations in automated blood tests and point-of-care diagnostics
• Asia-Pacific is expected to be the fastest-growing region in the pernicious anemia testing market during the forecast period due to increasing healthcare access, rising awareness, and growing investments in diagnostic infrastructure
• Vitamin B-12 Deficiency Test segment dominated the pernicious anemia testing market with a market share of 41.9% in 2024, driven by its reliability, non-invasiveness, and widespread use in routine screening and clinical diagnostics

Report Scope and Pernicious Anemia Testing Market Segmentation   

Pernicious Anemia Testing Market Trends

“Advancements in Non-Invasive and Automated Diagnostic Technologies”

• A significant and accelerating trend in the global pernicious anemia testing market is the adoption of non-invasive, automated, and rapid diagnostic technologies, enhancing test accuracy, efficiency, and patient convenience
• For instance, the Advia Centaur Vitamin B12 assay enables fully automated testing in clinical laboratories, reducing manual intervention and turnaround time for results
• AI and machine learning integration in testing platforms allows predictive analytics for early detection of vitamin B12 deficiency and pernicious anemia, enabling clinicians to make data-driven treatment decisions
• These automated and intelligent testing systems facilitate centralized laboratory workflows, allowing multiple hematology and biochemistry parameters to be analyzed simultaneously for a comprehensive patient evaluation
• This trend towards more accurate, faster, and patient-friendly testing solutions is reshaping clinician and patient expectations, prompting companies such as Roche Diagnostics to develop automated and AI-enabled testing platforms
• The demand for rapid, non-invasive, and high-throughput diagnostic solutions is growing rapidly across both hospitals and diagnostic centers, as healthcare providers prioritize efficiency, accuracy, and patient comfort

Pernicious Anemia Testing Market Dynamics

Driver

“Rising Prevalence of Vitamin B12 Deficiency and Awareness”

• The increasing prevalence of vitamin B12 deficiency, coupled with growing awareness of pernicious anemia and related health risks, is a significant driver for the heightened demand for diagnostic testing
• For instance, in 2024, Quest Diagnostics launched targeted campaigns to raise awareness about vitamin B12 deficiency testing in at-risk populations, aiming to improve early detection rates
• As healthcare providers recognize the importance of early diagnosis, testing for pernicious anemia has become integral to routine check-ups and preventive healthcare, especially for aging populations
• Furthermore, advancements in laboratory automation and non-invasive testing methods make it easier to integrate pernicious anemia testing into standard clinical workflows
• Increased patient demand for reliable, fast, and minimally invasive testing options, combined with the expansion of diagnostic centers, is further propelling market adoption across hospitals, clinics, and home care settings

Restraint/Challenge

“Testing Costs and Limited Awareness in Emerging Regions”

• Concerns surrounding the relatively high cost of advanced diagnostic tests and limited awareness of pernicious anemia in certain regions pose significant challenges to broader market penetration
• For instance, in developing countries, low patient awareness and limited healthcare infrastructure reduce routine testing for vitamin B12 deficiency and pernicious anemia
• Addressing these challenges through cost-effective testing solutions, government screening initiatives, and public awareness campaigns is crucial for expanding market reach
• In addition, inconsistent insurance coverage for diagnostic testing can discourage patients from undergoing routine screening, limiting adoption despite the availability of advanced tests
• While testing technologies are becoming more efficient and automated, perceived costs and lack of awareness in price-sensitive or underserved regions continue to hinder widespread adoption
• Overcoming these barriers through educational programs, affordable testing kits, and improved healthcare access will be vital for sustained growth in the pernicious anemia testing market

Pernicious Anemia Testing Market Scope

The market is segmented on the basis of diagnosis test, route of administration, test type, and end user.

• By Diagnosis Test

On the basis of diagnosis test, the pernicious anemia testing market is segmented into Complete Blood Count (CBC) Test, Vitamin B-12 Deficiency Test, biopsy, and intrinsic factor deficiency test. The Vitamin B-12 Deficiency Test segment dominated the market with the largest market revenue share of 41.9% in 2024, driven by its high accuracy, non-invasive nature, and routine adoption in clinical practice. Healthcare providers prefer this test for early detection and monitoring of pernicious anemia. Automated analyzers and improved assay technologies have increased efficiency and throughput in hospitals and diagnostic centers. Patients favor it due to minimal discomfort compared to invasive procedures. The test is widely integrated into standard laboratory workflows, ensuring reliable and repeatable results. Its scalability makes it suitable for mass screening and preventive healthcare programs.

The Intrinsic Factor Deficiency Test segment is anticipated to witness the fastest growth from 2025 to 2032, fueled by rising awareness of autoimmune causes of pernicious anemia. This test confirms the exact etiology of vitamin B-12 deficiency, guiding targeted therapy. Increasing adoption in specialized hematology clinics and advanced diagnostic centers supports rapid growth. Technological advancements have made the test faster and more cost-effective, encouraging broader uptake. Growing prevalence of at-risk populations globally further accelerates segment expansion. Its clinical importance in precision diagnosis is driving demand in both developed and emerging markets.

• By Route of Administration

On the basis of route of administration, the pernicious anemia testing market is segmented into parenteral, oral, nasal, and topical. The Parenteral segment dominated the market in 2024, due to rapid effectiveness in correcting severe vitamin B-12 deficiency and established clinical trust. Injections are preferred in hospitals and clinics for immediate therapeutic intervention. This route ensures full bioavailability, especially for patients with impaired gastrointestinal absorption. Parenteral administration is widely recommended in initial treatment phases, followed by maintenance therapy via other routes. Hospitals favor this route for controlled dosing and accurate monitoring of patient response. Strong adherence to standardized treatment protocols maintains dominance in this segment.

The Oral segment is expected to witness the fastest growth from 2025 to 2032, driven by increasing patient preference for convenience and non-invasive administration. Oral supplements are gaining traction in homecare and outpatient settings due to ease of use and improved compliance. High-dose oral therapies have demonstrated effectiveness even in patients with absorption difficulties. Home-based treatment trends and telemedicine initiatives further accelerate adoption. Affordability and OTC availability of oral formulations support rapid uptake. Patient education on oral therapy efficacy contributes to strong growth potential.

• By Test Type

On the basis of test type, the pernicious anemia testing market is segmented into Vitamin B-12 Injections and Vitamin B-12 Pills. The Vitamin B-12 Injections segment dominated the market in 2024, owing to rapid correction of deficiency, clinical reliability, and extensive hospital adoption. Injections are preferred for severe pernicious anemia, ensuring immediate replenishment of B-12 levels. Healthcare providers favor controlled dosing and monitoring of patient response. Injections are especially recommended for patients with absorption issues where oral therapy is insufficient. Automated delivery devices and safety features further encourage hospital use. Established treatment protocols and clinician trust reinforce segment dominance.

The Vitamin B-12 Pills segment is expected to witness the fastest growth from 2025 to 2032, fueled by rising patient demand for convenience, self-administration, and non-invasive therapy. Pills are increasingly popular in homecare settings and long-term maintenance therapy. High-dose formulations and research supporting oral therapy efficacy drive adoption. OTC availability and lower cost compared to injections enhance uptake in emerging markets. Telehealth and patient education campaigns further accelerate segment growth. Improved compliance and convenience make oral pills a preferred option for many patients.

• By End User

On the basis of end user, the pernicious anemia testing market is segmented into hospitals, diagnostic centers and clinics, and homecare. The Hospitals segment dominated the market in 2024, driven by high patient inflow, advanced diagnostic facilities, and capacity to manage severe cases. Hospitals handle initial diagnosis, treatment initiation, and follow-up monitoring. Integrated workflows combine CBC, vitamin B-12, and intrinsic factor deficiency tests for accurate diagnosis. Trained medical professionals and automation ensure efficient and reliable testing. Insurance coverage and government health programs support routine screening. Centralized care and clinical trust make hospitals the primary end user segment.

The Homecare segment is expected to witness the fastest growth from 2025 to 2032, driven by rising adoption of at-home testing kits, oral supplementation, and telemedicine support. Patients prefer homecare solutions for convenience, privacy, and reduced hospital visits. Rapid diagnostic kits and digital monitoring systems enable accurate testing and therapy management at home. Aging populations and chronic disease prevalence drive demand for remote care. Partnerships between diagnostic companies and telehealth providers accelerate growth. Education campaigns and increased accessibility of home-based therapy further support segment expansion.

Pernicious Anemia Testing Market Regional Analysis

• North America dominated the pernicious anemia testing market with the largest revenue share of 38.2% in 2024, characterized by advanced healthcare infrastructure, high awareness levels, and a strong presence of key diagnostic companies
• Healthcare providers in the region prioritize early detection and management of vitamin B-12 deficiency and pernicious anemia, leveraging automated and high-throughput testing solutions for accurate diagnosis
• Widespread adoption is further supported by strong insurance coverage, government health initiatives, and a technologically inclined medical workforce, establishing pernicious anemia testing as a routine part of preventive and clinical care in both hospitals and diagnostic centers

U.S. Pernicious Anemia Testing Market Insight

The U.S. pernicious anemia testing market captured the largest revenue share of 81% in 2024 within North America, fueled by advanced healthcare infrastructure, high awareness of vitamin B-12 deficiency, and widespread adoption of automated diagnostic technologies. Patients and clinicians increasingly prioritize early detection and management of pernicious anemia through routine blood tests and comprehensive screening panels. The growing preference for non-invasive, home-based, and point-of-care testing solutions further propels market growth. Moreover, robust insurance coverage, government health initiatives, and the integration of digital health platforms contribute significantly to market expansion.

Europe Pernicious Anemia Testing Market Insight

The Europe pernicious anemia testing market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing awareness of anemia-related health risks and rising adoption of advanced diagnostic methods. Urbanization, coupled with greater access to healthcare services, is fostering the uptake of testing solutions in hospitals, clinics, and diagnostic centers. European healthcare providers are also emphasizing preventive care and early diagnosis, which is boosting market growth. The region is experiencing significant adoption across both residential and outpatient healthcare settings.

U.K. Pernicious Anemia Testing Market Insight

The U.K. pernicious anemia testing market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by rising awareness of vitamin B-12 deficiency, increased government health programs, and the adoption of non-invasive diagnostic technologies. Concerns regarding anemia-related complications are encouraging healthcare providers and patients to opt for regular testing. The U.K.’s robust healthcare infrastructure, combined with widespread availability of advanced testing kits, continues to stimulate market growth.

Germany Pernicious Anemia Testing Market Insight

The Germany pernicious anemia testing market is expected to expand at a considerable CAGR during the forecast period, fueled by high awareness of early diagnosis, demand for technologically advanced diagnostic solutions, and emphasis on preventive healthcare. Germany’s well-established healthcare system and focus on innovation promote the adoption of automated testing platforms and advanced blood assays. Integration of testing with broader clinical workflows is also becoming increasingly prevalent, with a strong preference for accuracy, reliability, and patient convenience.

Asia-Pacific Pernicious Anemia Testing Market Insight

The Asia-Pacific pernicious anemia testing market is poised to grow at the fastest CAGR of 24% during the forecast period of 2025 to 2032, driven by increasing healthcare access, rising disposable incomes, and growing awareness of vitamin B-12 deficiency in countries such as China, Japan, and India. Expansion of diagnostic centers, government health initiatives promoting early detection, and improvements in laboratory infrastructure are driving adoption. In addition, the rising use of home-based testing kits and telemedicine platforms is enhancing accessibility across the region.

Japan Pernicious Anemia Testing Market Insight

The Japan pernicious anemia testing market is gaining momentum due to the country’s aging population, high healthcare standards, and emphasis on preventive medicine. Early diagnosis and management of pernicious anemia are increasingly prioritized through routine blood tests and vitamin B-12 monitoring. Integration of testing with digital health platforms and hospital information systems is fueling growth. Moreover, Japan’s focus on convenience, patient-friendly diagnostic procedures, and advanced healthcare technology is driving adoption in both residential and clinical settings.

India Pernicious Anemia Testing Market Insight

The India pernicious anemia testing market accounted for the largest revenue share in Asia-Pacific in 2024, attributed to the expanding middle class, growing healthcare awareness, and increasing availability of diagnostic services. India is witnessing rapid adoption of automated vitamin B-12 testing and home-based diagnostic kits. The expansion of government health programs, rising private healthcare investments, and affordable testing solutions are key factors propelling market growth. Increasing prevalence of vitamin B-12 deficiency and improved healthcare infrastructure further support market expansion across urban and semi-urban regions.

Pernicious Anemia Testing Market Share

The Pernicious Anemia Testing industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• University of Oxford (U.K.)
• The Pernicious Anaemia Society (U.K.)
• MedRxiv (U.S.)
• The General Hospital Corporation (U.S.)
• Lupin (India)
• True Health Labs (U.S.)
• James Lind Alliance (U.K.)
• Genova Diagnostics (GDX) (U.S.)
• LabCorp (U.S.)
• Quest Diagnostics (U.S.)
• Bio-Rad Laboratories (U.S.)
• Siemens Healthineers AG (Germany)
• AbbVie Inc. (U.S.)
• F. Hoffmann-La Roche (Switzerland)
• QuidelOrtho Corporation (U.S.)
• BIOMÉRIEUX (France)
• QIAGEN (Germany)

What are the Recent Developments in Pernicious Anemia Testing Market?

• In April 2025, a comprehensive study published in Nature Reviews Endocrinology emphasized the necessity for clearer diagnostic protocols for pernicious anemia (PA). The research highlighted the challenges clinicians face due to the condition's complexity and the limitations of current diagnostic tests. It advocated for enhanced clinician education to improve patient outcomes
• In March 2025, the European Journal of Clinical Nutrition published a study discussing the 2024 NICE guidelines on vitamin B12 deficiency. The guidelines have significant implications for the diagnosis and management of PA, suggesting clearer diagnostic protocols and emphasizing the need for clinician education to improve the patient journey for those with PA
• In November 2024, The Pernicious Anaemia Society, in collaboration with the James Lind Alliance, conducted a priority-setting partnership to identify the top research priorities for pernicious anemia. This initiative aims to guide future research and improve patient outcomes
• In August 2024, a study published in MedRxiv surveyed members of the Pernicious Anaemia Society to identify and characterize a cohort of patients for a PA research repository. The study aimed to enhance understanding and research into PA by gathering detailed patient-reported characteristics
• In June 2022, Researchers from the University of Oxford are collaborating with the Pernicious Anaemia Society to investigate better treatment options for pernicious anemia. The current treatment methods have been in use for over sixty years, and this collaboration seeks to explore new approaches

SKU-57459